Demo Page – Page 4

Left Ventricular Ejection on Fraction, Ventricular Remodelling and Outcomes After Sacubitril – Valsartan in a Real-Life Cohort

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Sacubitril–valsartan (SV) has demonstrated prognostic benefits in patients with heart failure with reduced ejection fraction (HFrEF), although its long-term impact in real-world clinical practice remains unclear. This study assessed long-term outcomes associated with SV use in a real-world HFrEF cohort. The findings were presented at Heart Failure 2026, […]

Left Ventricular Ejection on Fraction, Ventricular Remodelling and Outcomes After Sacubitril – Valsartan in a Real-Life Cohort Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Heart Failure Biomarkers, Heart Failure Prognosis, Heart Failure with Reduced Ejection Fraction (HFrEF), NT-proBNP, Risk Stratification in Heart Failure

The Prognostic Value of NT-proBNP Variability Measured During Rou ne Follow-Up in Outpatients with Heart Failure with Reduced Ejection Fraction

by Prateek Chopra | May 19, 2026 | Cardiology Conferences | ESC-HF 2026 N-terminal pro–B-type natriuretic peptide (NT-proBNP) is an established biomarker for risk stratification in Heart Failure with reduced ejection fraction (HFrEF). However, the prognostic significance of serial variability in NT-proBNP levels during routine follow-up in clinically stable patients remains unclear. This study aimed to determine whether fluctuations in NT-proBNP

The Prognostic Value of NT-proBNP Variability Measured During Rou ne Follow-Up in Outpatients with Heart Failure with Reduced Ejection Fraction Read Post »

Phenotypic Clusters and Sacubitril/Valsartan in Heart Failure with PreservedEjec on Frac on: A PARAGON-HF Substudy

by Prateek Chopra | May 18, 2026 | Cardiology Conferences | ESC-HF 2026 Heart Failure with preserved ejection fraction (HFpEF) is a clinically heterogeneous syndrome with substantial variability in patient characteristics, prognosis, and therapeutic response. Despite advances in HF management, treatment outcomes in HFpEF remain inconsistent, likely reflecting differences in underlying pathophysiological mechanisms across patient subgroups. Machine learning–based phenotyping has emerged

Phenotypic Clusters and Sacubitril/Valsartan in Heart Failure with PreservedEjec on Frac on: A PARAGON-HF Substudy Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Heart Failure with Preserved Ejection Fraction (HFpEF), Machine Learning in Cardiology, PARAGON-HF Trial, Precision Heart Failure Medicine, Sacubitril/Valsartan (ARNI)

Type 2 Diabetes and Chronic Kidney Disease Combina ons in Heart Failure Acrossthe Ejec on Frac on Spectrum: Clinical Associa ons, Medica on Use, andCause-Specific Outcomes

by Prateek Chopra | May 18, 2026 | Cardiology Conferences | ESC-HF 2026 Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) frequently coexist with Heart Failure (HF), substantially increasing the risks of mortality and hospitalization for HF (HHF). Several HF therapies have demonstrated cardiorenal benefits in patients with CKD and/or T2DM; however, real-world evidence suggests that these therapies remain

Type 2 Diabetes and Chronic Kidney Disease Combina ons in Heart Failure Acrossthe Ejec on Frac on Spectrum: Clinical Associa ons, Medica on Use, andCause-Specific Outcomes Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiorenal Syndrome, Guideline-Directed Medical Therapy (GDMT), Heart Failure and Chronic Kidney Disease (CKD), Heart Failure Outcomes, Type 2 Diabetes (T2DM)

Opmizing Heart Failure Treatment in Pa ents Receiving Renal ReplacementTherapy: The Role of a Cardiorenal Unit

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Cardiorenal syndrome (CRS) remains a major therapeutic challenge, particularly in patients receiving renal replacement therapy, where evidence supporting guideline-directed Heart Failure (HF) therapies is limited. The management of these patients is often complicated by multiple comorbidities, fluid overload, and concerns regarding treatment tolerability and safety. This study aimed

Opmizing Heart Failure Treatment in Pa ents Receiving Renal ReplacementTherapy: The Role of a Cardiorenal Unit Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiorenal Syndrome (CRS), Guideline-Directed Medical Therapy (GDMT), Heart Failure Management, Multidisciplinary Heart Failure Care, Renal Replacement Therapy

PRAISE-MR – ARNI in HFpEF with Secondary MR

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Atrial functional MR (AFMR) in HFpEF is characterized by preserved LV function with left atrial enlargement and mitral annular dilatation, differing from ventricular SMR. Although randomized AFMR-specific trials have been lacking, emerging evidence with ARNI, SGLT2i, ARBs, beta-blockers, CRT, and M-TEER suggests AFMR is a potentially treatable condition.

PRAISE-MR – ARNI in HFpEF with Secondary MR Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Atrial Functional Mitral Regurgitation (AFMR), Heart Failure with Preserved Ejection Fraction (HFpEF), Mitral Regurgitation Management, PRAISE-MR Trial, Sacubitril/Valsartan (ARNI)

Vericiguat: Standard Therapy for HFrEF

by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) continued to experience substantial morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT). The prognosis after worsening heart failure (HF) events remained poor, with approximately 37% 1-year all-cause mortality/HFH rates and 19% 1-year mortality despite optimized medical and device

Vericiguat: Standard Therapy for HFrEF Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Guideline-Directed Medical Therapy (GDMT), Heart Failure with Reduced Ejection Fraction (HFrEF), Vericiguat, VICTORIA Trial, Worsening Heart Failure

GDMT in HFrEF: A Complete Story or a Par al Narrative?

by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 The guideline-directed medical therapy (GDMT) has transformed the prognosis of heart failure with reduced ejec on frac on (HFrEF). The introduc on of the four founda onal pillars, ARNIs or ACE inhibitors, beta-blockers, Mineralocor coid receptor antagonists, and SGLT2 inhibitors, has substan ally reduced mortality and hospitaliza on.

GDMT in HFrEF: A Complete Story or a Par al Narrative? Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Guideline-Directed Medical Therapy (GDMT), Heart Failure 2026, Heart Failure with Reduced Ejection Fraction (HFrEF), Vericiguat, Worsening Heart Failure

The HFrEF Medica on Toolkit for Pa ents Who Need More: From Evidence to Implementation

by Prateek Chopra | May 14, 2026 | Cardiology Conferences | ESC-HF 2026 The session highlighted that heart failure with reduced ejec on frac on (HFrEF) has entered a contemporary treatment era characterized by rapid and comprehensive implementa on of evidence-based therapies. Despite major advances with the four founda onal pillars, ACE inhibitors/ARNIs, beta-blockers, Mineralocor coid receptor antagonists, and SGLT2 inhibitors,

The HFrEF Medica on Toolkit for Pa ents Who Need More: From Evidence to Implementation Read Post »

What are HFimpEF, HFrecHF, and HFremEF?

by Prateek Chopra | May 14, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure phenotypes characterized by improvement or recovery in le ventricular ejec on frac on (LVEF) have emerged as important clinical en es, leading to the evolving concepts of heart failure with improved ejec on frac on (HFimpEF), heart failure with recovered heart failure (HFrecHF/HFrecEF), and heart failure

What are HFimpEF, HFrecHF, and HFremEF? Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Ambulatory Blood Pressure Monitoring (ABPM), Home Blood Pressure Monitoring (HBPM), Hypertension Management, Patient-Centered Hypertension Care, Single-Pill Combination Therapy (SPC)